ASH 2015: New LIM Kinase inhibitor data on AML mutations with high unmet medical need

During the 57th American Society of Hematology Congress held in Orlando, the teams from U. of Indiana Wells Center led by Pr Kapur and Institut Albert Bonniot led by Dr Lafanechère presented the results of their work in the session dedicated to Oncogene and Tumor Suppressors in Myeloïd malignancies. This new data reinforces the rationale for looking into LIM Kinase inhibition to stop downstream oncogene signaling of specific mutations of Tyrosine Kinase Receptors.

read more